The renal biomarkers market in the Middle East & Africa is anticipated to grow from USD 61.15 million in 2023 to USD 80.22 million by 2028, growing at a CAGR of 5.58% from 2023 to 2028
The growing incidence of various kidney-related disorders and the increasing prevalence of diabetes and blood pressure primarily drive the growth of the renal biomarkers market in MEA. These factors have fueled the demand for renal biomarkers, which can effectively diagnose and detect individuals at risk of developing kidney disease by monitoring their blood or urine levels. Moreover, with the advent of computer technology, renal biomarker testing has become increasingly accessible, even in small laboratories, which has further driven market expansion. As a result, the renal biomarkers market is poised for substantial growth, providing lucrative opportunities for businesses operating in this sector.
The growing support from the governments of MEA countries and increasing investments in the R&D of renal markers contribute to the growth of the MEA renal biomarkers market. The market participants have been putting increased efforts into the development of advanced devices that can accurately measure renal biomarkers and enable early detection of renal failure, thus preventing critical situations. Researchers are exploring the potential for developing similar devices to monitor renal biomarkers in animals, particularly in light of the increasing prevalence of kidney failure in pet animals such as dogs and cats. Such investments and initiatives drive growth and innovation in the renal biomarkers market.
The growing incidence of geriatric and pediatric renal cases boosts the growth rate of the MEA renal biomarkers market. Renal failure is a chronic condition that can impact patients throughout their lifespan and may even lead to end-stage renal failure and ultimately, death. As individuals age, they become more susceptible to kidney and urinary tract problems, with the potential for such issues to result in cardiovascular diseases such as valve damage and heart stroke. To mitigate these risks, governments in various regions are conducting awareness programs that encourage individuals over the age of 60 to undergo regular renal biomarker testing. By detecting potential kidney issues early on, patients can take proactive steps to prevent dangerous situations and improve their overall quality of life. These trends are expected to continue driving growth in the renal biomarkers market in the Middle East and Africa.
The high costs associated with the biomarker process are one of the key factors hampering the growth of the MEA renal biomarkers market. Teed for greater awareness of the renal biomarker test, the scarcity of skilled professionals in the laboratories, and the lengthy approval process for new renal testing devices further hinder the growth of the regional market. Furthermore, inadequate infrastructure facilities in testing centers may lead to inaccurate results, which could have serious implications for patient health and is another significant roadblock to the growth of the MEA renal biomarkers market.
This research report on the Middle East & Africa renal biomarkers market has been segmented and sub-segmented into the following categories.
By Diagnostic Technique:
By Type:
By Country:
The renal biomarkers market in the MEA region accounted for a moderate share of the worldwide market in 2023. However, the regional market is anticipated to register a healthy CAGR during the forecast period owing to factors such as the rising prevalence of kidney-related diseases, diabetes, and other ailments. In particular, chronic kidney disease has emerged as a major concern, affecting a substantial portion of the global population, with a majority of cases being in the advanced stages. Notably, recent research indicates that the incidence of chronic kidney disease stages among UAE nationals has risen by 4.6 percent in males and 2.8 percent in females. These trends underscore the need for innovative solutions in the renal biomarkers market, presenting a promising opportunity for businesses in the region. Also, it is estimated that 80% of this expense is borne by low- or middle-income countries, with 25 percent held by individuals under the age of 60 as chronic kidney disease is a global public health problem. For example, Saudi Arabia has over 16,000 people with renal failure, with 60 percent on dialysis and 6,000 awaiting kidney transplants, increasing the demand for renal biomarkers, positively impacting the renal biomarkers market.
The South Africa renal biomarkers market is projected to account for a considerable share of the MEA market in the coming years owing to the growing prevalence of various kidney-related diseases, the availability of improving healthcare facilities, and growing healthcare expenditure in the region.
KEY MARKET PLAYERS:
Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd are some of the notable companies in the MEA renal biomarkers market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region